drugset / Trial / NCT00144053
A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.
Timeline
- Start
- 2001-04
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | MMC | Unknown | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Vindesine | Small molecule | — | — |